DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: In particular, CD26 (dipeptidylpeptidase IV) is considered a potential biomarker for the identification and quantification of CML LSCs, able to discriminate CML LSCs from normal hematopoietic stem cells from LSCs of other myeloid neoplasms (Galimberti et al., 2018; Sicuranza et al., 2022).